Related Experiment Video
Updated: May 20, 2025
14:24
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
11.6K
Cancer-Therapy-Related Cardiac Dysfunction: Latest Advances in Prevention and Treatment
Carla Contaldi1, Carmine D'Aniello2, Domenico Panico3
1Department of Cardiology, AORN dei Colli-Monaldi Hospital, 80131 Naples, Italy.
Life (Basel, Switzerland)
|March 27, 2025
Summary
Cancer therapies improve survival but can cause cardiac dysfunction (CTRCD). Early detection, prevention with medications and lifestyle changes, and new technologies are key to managing CTRCD and improving patient outcomes.
Area of Science:
- Cardiology
- Oncology
- Pharmacology
Background:
- Cancer therapies enhance survival but increase risks of cancer-therapy-related cardiac dysfunction (CTRCD).
- CTRCD arises from treatments like anthracyclines, HER2-targeted therapies, and radiotherapy.
- Understanding CTRCD mechanisms is vital for managing cardiovascular complications in cancer patients.
Purpose of the Study:
- To provide a comprehensive review of CTRCD identification, monitoring, and management.
- To discuss mechanisms of CTRCD related to various cancer treatments.
- To highlight emerging technologies for personalized CTRCD prevention and treatment.
Main Methods:
- Review of current literature on CTRCD.
- Discussion of diagnostic tools including serum biomarkers and advanced imaging.
- Analysis of pharmacological and lifestyle interventions for prevention and management.
Main Results:
- Early detection via biomarkers and imaging is crucial for risk stratification.
- Pharmacological interventions (ACE inhibitors, beta-blockers, statins) and novel agents show promise.
- Lifestyle modifications like exercise and nutrition aid cardioprotection.
Conclusions:
- Integrated strategies involving early detection, prevention, and tailored treatments are essential for CTRCD.
- Emerging technologies like AI and genomics offer personalized approaches to CTRCD management.
- Minimizing cardiovascular complications through advanced strategies improves long-term outcomes for cancer survivors.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
354
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
354
02:49Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
01:26Heart Failure Drugs: Inotropic Agents
476
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
476
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
123
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
123
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K